Introduction
E2F transcription factors are key players in the regulation of proliferation, apoptosis, and dierentiation in mammalian cells (Dyson, 1998; Nevins, 1998; Muller and Helin, 2000) . There are six members of the E2F family. E2Fs form heterodimeric complexes with the DP family of proteins (DP-1, DP-2). Considering alternative promoter/exon use with E2F-3 (-3a, -3b) (Leone et al., 2000) and alternative splicing with DP-2 (Ormondroyd et al., 1995) , the number of E2F/DP heterodimers that may form is quite large. The E2F family may be divided into three subfamilies based on their binding to members of the retinoblastoma tumor suppressor family (Rb, p107, p130) . E2F-1, -2 and -3 preferentially bind Rb, E2F-4 preferentially binds p107 and p130, E2F-5 binds p130, while E2F-6 lacks sequences required for Rb binding. E2F/DP heterodimers bind to Rb family members using a C-terminal domain in conjunction with internal sequences within E2F (marked box) and DP (corresponding region) (Helin et al., 1993) . The interaction of E2Fs with Rb family members occurs at speci®c stages of the cell cycle. In G 0 , the predominant E2F complexes are E2F-4/DP and E2F-5/DP with p130 (Dyson, 1998) . Following growth factor stimulation, the E2F-5/p130 complex diminishes and E2F-1/DP bound to Rb and E2F-4/DP bound to p107 are evident. The activation of G 1 cyclin dependent kinases (cyclin D/cdk4, cyclin E/cdk2) results in hyper-phosphorylation of Rb family members and their release from E2Fs (Dyson, 1998) . Free' E2F activity is evident during late G 1 and into S phase of the cell cycle, and transactivates promoters of E2F-responsive genes. E2Fs control the expression of genes involved in G 1 and S phase progression. During S phase, p107 expression is induced which represses E2F-4/DP, and E2F-1/DP is down-regulated by multiple mechanisms (Muller and Helin, 2000) . Rb family members interact with E2Fs via the conserved pocket domain, which mediates binding to DNA tumor virus oncoproteins, as well as sequences C-terminal of this region (Hiebert, 1993; Zhu et al., 1993b) .
E2F-1 was the ®rst member cloned and it is the best characterized E2F activity. The E2F-1 protein has the properties of both an oncogene and a tumor suppressor, depending on the context in which E2F-1 function is analysed. E2F-1 expression is sucient to drive quiescent cells to enter S phase of the cell cycle (Johnson et al., 1993; Qin et al., 1994; Shan and Lee, 1994) and to cooperate with activated Ras to transform cells in culture and induce tumors in nude mice (Johnson et al., 1994a; Singh et al., 1994; Xu et al., 1995) . E2F-1 over-expression promotes hyperplasia and can cooperate with activated Ras or inactivated p53 to promote tumor formation (Pierce et al., 1998a,b) . E2F-1 over-expression also prevents terminal dierentiation of certain cell types (Guy et al., 1996) . These properties appear to relate to transcriptional activation by E2F-1 and its ability to turn on the expression of genes that promote cell cycle progression (e.g., c-myc, B-myb, cdc25A, cyclin E) and S phase (e.g. DNA synthesis genes, cyclin A, cdc2). The analysis of E2F-1 knock-out mice has shown that the protein also has properties of a tumor suppressor since these mice are prone to develop tumors (Field et al., 1996; Yamasaki et al., 1996) . Thus, E2F-1 plays roles in cell growth, death, and dierentiation decisions of the cell.
The apparent contradictory ability of E2F-1 to function as an oncogene and tumor suppressor likely re¯ect the ability of E2Fs to positively and negatively regulate gene expression. E2F-1 likely acts as an oncogene by activating the expression of genes that promote cellular proliferation. When bound to promoters with a member of the Rb family, however, E2F may repress gene expression by virtue of the ability of Rb family members to recruit histone deacetylase complexes (HDACs) (Adnane et al., 1995; Bremner et al., 1995; Brehm et al., 1998; Ferreira et al., 1998; Luo et al., 1998) . Histone deacetylation is linked with repression of gene expression via a closed chromatin structure (Berger, 1999; Brown et al., 2000) . The repression of cellular genes by E2F/Rb may result in the loss of proliferative signals, and thus E2F-1 can act as a growth inhibitor. In addition, one important target of E2F-1 is the promoter for the tumor suppressor p19-ARF (Bates et al., 1998; Robertson and Jones, 1998; Zhu et al., 1999) . p19-ARF is an important upstream activator of p53 (Sherr and Weber, 2000) . The loss of E2F-1 in a knock-out mouse could promote tumor formation via inhibition of the p53 pathway for tumor suppression, and via the activation (i.e., derepression) of genes that promote proliferation.
E2F was ®rst described as a nuclear activity that bound to an inverted binding site in the adenovirus (Ad) E2a promoter (Kovesdi et al., 1986) . The binding of E2F to these sites is stimulated by the Ad E4-6/7 protein which induces the cooperative and stable binding of E2F to the E2a promoter via dimerization (Figure 1 ). The induction of E2F binding to the Ad E2a promoter in vitro directly correlates with transcriptional activation of the E2a promoter in vivo (Huang and Hearing, 1989; Neill et al., 1990; Obert et al., 1994) . The Ad E4-6/7 protein also transactivates the cellular E2F-1 promoter via the induction of E2F DNA binding to an inverted con®guration of binding sites at the sites of initiation of E2F-1 transcription (Figure 1 ; Schaley et al., 2000) . These results suggest that the Ad E4-6/7 protein may function as an analogue to a cellular counterpart that regulates E2F dimerization and stable DNA binding. In this report, we describe such a cellular activity. The cellular p107 tumor suppressor induces stable E2F-4/DP binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters. Such induction of E2F DNA binding requires the pocket domain of p107. p107 induction of E2F DNA binding occurs primarily in S phase when p107 protein levels increase signi®cantly and directly correlates with transcriptional repression. The related tumor suppressor, p130, also mediates this function. These results support a model in which p107 and p130 induce the stable binding of E2F complexes to promoters that drive expression of critical regulatory proteins such as E2F-1. Since p107 and p130 bind histone deacetylase complexes (HDACs) which repress promoter activity (Adnane et al., 1995; Bremner et al., 1995; Brehm et al., 1998; Ferreira et al., 1998; Luo et al., 1998) , p107-E2F and p130-E2F would stably recruit repressor complexes to eect ecient promoter repression.
Results

E2F
-4, DP-1 and p107 form a stable DNA-protein complex on inverted E2F binding sites
The adenovirus E4-6/7 protein forms a stable complex with E2F/DP family members in solution and induces the cooperative and stable binding of E2Fs to inverted DNA binding sites in the Ad E2a and cellular E2F-1 promoter regions. This result and the fact that the inverted con®guration of E2F binding sites is conserved within the human and mouse E2F-1 promoter regions (Hsiao et al., 1994; Johnson et al., 1994b) led us to hypothesize that Ad E4-6/7 may have evolved as an analogue to a cellular protein with similar function. To test this idea, we surveyed nuclear extracts from dierent cell types by electrophoretic mobility shift assay (EMSA) for an E2F-speci®c binding activity that bound in a stable manner to an E2F inverted repeat, but not to a single E2F binding site ± the notable property of Ad-induced E2F activity. Such an activity was readily apparent in nuclear extracts from many dierent cell sources and a representative experiment using HeLa cell nuclear extract is shown in Figure 2a .
Comparison of E2F complexes formed on a single E2F binding site (lane 1) to those formed on the Ad E2a promoter (lane 2) and the cellular E2F-1 promoter (lane 4), both of which contain an inverted con®gura-tion of E2F binding sites, revealed four common complexes (free E2F, E2F/Rb and E2F/p107) as well as a novel, slow-migrating complex formed speci®cally on inverted E2F sites. That the inverted con®guration of E2F binding sites was required for the formation of this complex was con®rmed using an Ad E2a promoter probe containing a linker scanning mutation in the upstream E2F binding site (lane 3). The hallmark on the Ad-induced E2F complex on the viral E2a and cellular E2F-1 promoter regions is that the complex is stable to challenge with excess E2F binding site competitor DNA. This property was shared by the cellular activity that bound the E2F inverted binding sites since the complex, once formed on the probe DNA, was resistant to competition by the addition of a 500-fold molar excess of unlabeled E2F sites, whereas the other E2F-speci®c complexes were eciently competed from the probe DNAs (lanes 5 ± 8). All of the E2F-speci®c complexes were competed when the unlabeled E2F competitor DNA was added simultaneously with the probe DNAs (lanes 9 ± 12), showing that the complex termed stable E2F was indeed bound in a stable manner to the inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters.
To directly quantify the stability of E2F complexes formed on single and inverted E2F binding sites, an o-rate analysis was performed. Binding reactions were established using Hela cell nuclear extract with single or dimeric, inverted E2F site probes. Excess unlabeled E2F competitor DNA was added following a 60 min binding reaction (time 0), and aliquots of the binding reaction were withdrawn and analysed by EMSA 10, 20, 30 and 40 min following the addition of speci®c competitor DNA. The results were quanti®ed by phosphoimager analysis and a representative experiment is depicted in Figure 2b . Free E2F on a single E2F binding site displayed a half-life bound to the probe DNA of *5 min, whereas the stable E2F complex on the dimeric, inverted E2F site displayed a half-life of greater than 30 min.
To begin to determine the components of the stable E2F complex, speci®c monoclonal antibodies were used. Following E2F site competitor challenge of the A.
B.
Figure 2 (a) A cellular E2F complex binds in a stable manner to inverted E2F sites in viral and cellular promoter regions. Nuclear extract from HeLa cells was incubated with E2F site probe DNAs and DNA-protein complexes resolved by EMSA. Lane 1, an E2F single site probe; lane 2, probe corresponding to the E2F inverted binding sites in the Ad E2a promoter region; lane 3, Ad E2a probe with a linker scanning mutation in the upstream E2F binding site; lane 4, probe corresponding to the E2F inverted binding sites in the cellular E2F-1 promoter. Free E2F activity in HeLa nuclear extract corresponds predominantly to E2F-1 and E2F-4, based on antibody supershift analyses. E2F/Rb and E2F/ p107 single E2F site complexes were identi®ed using appropriate antibodies. Lanes 5 ± 8 correspond to the same probes as lanes 1 ± 4, but following a standard 1 h binding reaction a 500-fold molar excess of unlabeled E2F binding sites were added for 15 min prior to EMSA. Lanes 9 ± 12 correspond to the same probes as lanes 1 ± 4, but a 500-fold molar excess of unlabeled E2F binding sites was added simultaneously with the probe DNA. Lanes 13 ± 16, antibody supershift of the stable E2F complex. Binding reactions were established using HeLa nuclear extract and the Ad E2a promoter probe. Following binding and competition with excess unlabeled E2F binding sites, speci®c antibodies were added and the reaction was continued for 20 min before EMSA. (b) O-rate analysis of E2F complexes on single and inverted, double E2F binding sites. Binding reactions were established using Hela cell nuclear extract with single or dimeric, inverted E2F site probes. Excess unlabeled E2F competitor DNA was added following a 60 min binding reaction (time 0), and aliquots of the binding reaction were withdrawn and analysed by EMSA 10, 20, 30 and 40 min following the addition of speci®c competitor DNA. The results were quanti®ed by phosphoimager analysis and are presented as per cent E2F complex bound to probe DNA at the times indicated on the x axis. Free E2F on a single site probe: (X ± X), stable E2F on a dimeric, inverted site probe (& ± &) stable E2F complex formed on the Ad E2a promoter probe, antibodies speci®c to E2F-4 and p107 supershifted the complex, whereas antibodies against E2F-1 and Rb did not. Control experiments demonstrated that all four antibodies were capable of recognizing individual E2F complexes formed using HeLa cell nuclear extract (data not shown). We conclude that a cellular E2F complex binds in a stable manner to inverted con®gurations of E2F binding sites, and that this complex contains E2F-4 and p107.
To determine if E2F-4/DP and p107 are sucient to form the stable E2F complex in vitro reconstitution experiments were performed ( Figure 3 ). Free E2F activity present in Hela cell S-100 cytoplasmic extract was incubated with bacterially-expressed GST-p107 and analysed by EMSA using the Ad E2a probe. Free E2F binding activity was not stable to E2F competitor challenge (lanes 1 and 2) while the addition of p107 induced the formation of a complex that was as stable to competitor challenge as Ad-induced E2F (lanes 5 ± 8). The addition of GST-Rb to free E2F did not result in stable complex formation (lanes 3 and 4). E2F-4 and DP-1 were expressed in bacteria and analysed using the same approach. Free E2F-4/DP-1 formed a complex on the Ad E2a promoter that was not stable to competitor challenge (lanes 9 and 10) whereas p107 and Ad E4-6/7 induced the formation of a stable E2F-4/DP-1 complex (lanes 13 ± 16). Again, Rb was not eective in this activity. We conclude that E2F-4, DP-1 and p107 are sucient to form the stable E2F complex on inverted E2F binding sites.
The E2F binding region of p107 mediates E2F induction
The p107 coding region (1068 amino acids; Figure 8 ) may be divided into dierent functional intervals. The pocket region (amino acids 385 ± 949) contains sequences required for binding to DNA tumor virus oncoproteins such as SV40 T antigen (Ewen et al., 1992) . Within this domain are the A and B segments (amino acids 385 ± 584 and 781 ± 949, respectively) which interact with DNA tumor virus oncoproteins and a spacer region (amino acids 585 ± 780). Additional C-terminal sequences are required for E2F binding and growth suppression (Zhu et al., 1993a) . The N-terminal domain (amino acids 1 ± 384) contain a distinct growth suppression function (Zhu et al., 1993a) . To determine which p107 sequences are required for induction of stable E2F DNA binding, p107 mutant proteins were constructed and analysed using transient expression of Figure 4 The pocket domain of p107 mediated stable E2F DNA binding. 293T cells were cotransfected with expression vectors for E2F-4, DP-1, and wild type and mutant p107 proteins. Whole cell extracts were prepared following transfection and analysed for stable E2F-4/DP-1 DNA binding by EMSA using the Ad E2a promoter probe. Lane 1, 293T extract from untransfected cells. Lanes 2 ± 4, E2F-4+DP-1 alone; lanes 5 ± 16, E2F-4+DP-1+wild type p107 (lanes 5 ± 7), p107 D1 ± 384 (lanes 8 ± 10), p107 D585 ± 780 (lanes 11 ± 13), p107 D996 ± 1068 (lanes 14 ± 16). Lanes designated with (7) represent standard binding reactions. Lanes designated with t 0 represent binding reactions where a 500-fold molar excess of unlabeled E2F binding site competitor DNA was added simultaneously with the probe DNA. Lanes designated with t 60 represent binding reactions where a 500-fold molar excess of unlabeled E2F binding site competitor DNA was added following a standard 1 h binding reaction Figure 3 Reconstitution of the stable E2F complex in vitro using E2F-4, DP-1 and p107. (a) HeLa S100 cytoplasmic extract, an abundant source of free E2F activity, was incubated in the absence (7, lanes 1 and 2) or presence of GST-Rb (+Rb, lanes 3 and 4), GST-p107 (+p107, lanes 5 and 6) or GST-E4-6/7 (+E4-6/7, lanes 7 and 8) with Ad E2a probe and analysed by EMSA. Each binding reaction was incubated for 1 h. (+) indicates that DNA bound complexes were challenged with a 500-fold molar excess of unlabeled E2F site DNA for 15 min prior to EMSA (lanes 2, 4, 6 and 8). The arrow (left) indicates stable E2F DNA bound complexes induced by p107 and E4-6/7 proteins. (b) Bacterially-expressed human E2F-4 and human DP-1 were mixed and incubated with the Ad E2a promoter probe in the absence (7, lanes 9 and 10) or presence of GST-Rb (+Rb, lanes 11 and 12), GST-p107, lanes 13 and 14) or GST-E4-6/7 (+E4-6/7, lanes 15 and 16) and analysed by EMSA. Each reaction was incubated for 1 h prior to competitor challenge (+, lanes 10, 12, 14 and 16). The arrow (right) indicates stable E2F DNA bound complexes induced by p107 and E4-6/7 proteins proteins in transfected cells (Figure 4 ). 293T cells were transfected with expression plasmids for E2F-4, DP-1 and wild type or mutant p107 proteins. p107 mutants included a deletion of the N-terminal domain (D1 ± 384), the spacer region with the pocket domain (D585 ± 780), and part of the C-terminal region (D996 ± 1068) which is not required for binding to E2F (Zhu et al., 1993a) . E2F-4/DP-1 DNA binding was analysed by EMSA using the Ad E2a promoter probe and the induction of stable DNA-protein complexes was tested by the addition of excess unlabeled E2F site competitor DNA, as described above. All four p107 proteins were capable of inducing E2F complexes that were resistant to competitor challenge once bound to the probe DNA (lanes 5, 7, 8, 10, 11, 13, 14, and 16 ) whereas E2F-4/ DP-1 was not. All of the E2F-speci®c complexes were eciently competed when the unlabeled E2F site competitor DNA was added simultaneously with the probe DNA. E2F4-p107 complexes were detected in transfected 293-T cell cell extracts presumably due to overexpression of p107 relative to the levels of endogenous E1A and SV40 T antigen proteins. Identical results were observed with the p107 mutant proteins in transfected C33A cells that do not express viral oncoproteins (data not shown). We conclude that the minimal sequences of p107 that mediate E2F stable DNA-protein complex formation correspond to the minimal sequences that are required for E2F interaction.
Formation of the E2F-4/p107 stable DNA-protein complex during S phase of the cell cycle To begin to address the function of the stable E2F-4/ p107 DNA-protein complex during the cell cycle, we prepared extracts from synchronized SW3T3 cells. Cells were growth-arrested by allowing monolayer cultures to reach con¯uence followed by serumstarvation for 24 h. The cells were then replated in medium containing 10% FBS and harvested for extract preparation at dierent time-points. E2F-4/ p107 DNA-protein complexes were analysed by EMSA ( Figure 5 ). In growth-arrested cells, the prominent E2F complex contained p130 (lane 1), as reported in the literature (Chittenden et al., 1993; Cobrinik et al., 1993; Moberg et al., 1996) and veri®ed using speci®c antibodies (data not shown). Two E2F-4/p107 complexes were evident that began to appear 12 h after serum-stimulation (lane 4) coincident with the loss of the E2F-p130 complex. Both E2F-4/p107 DNA-protein complexes were found at more abundant levels at the 16 h time point and during the remainder of the time points evaluated (lanes 5 ± 9). That these two complexes contained E2F-4 and p107 was veri®ed using speci®c antisera (data not shown). The faster migrating E2F-4/p107 complex formed on both E2F single site and double site probes, while the more slowly migrating E2F-4/p107 complex only formed on the E2F double site probe (lanes 13 and 14). The more slowly migrating E2F-4/p107 complex was stably bound to DNA while the faster migrating complex was not, as measured using o-rate analyses (data not shown). The stable E2F-4/p107 DNA binding activity also was readily apparent in proliferating SW3T3 cell extracts (lane 10). The appearance of these E2F-4/p107 complex coincided with an increase in p107 protein levels as measured by Western blot analysis (Figure 5b) , whereas E2F-4 protein levels were evident throughout the cell cycle in SW3T3 cells, as reported in the literature with other cell lines (Moberg et al., 1996) . Propidium iodide Figure 5 Induction of stable E2F DNA binding during cell cycle progression. SW3T3 cells were growth-arrested, and then stimulated to proliferate by replating and the addition of serum. (a) Nuclear extracts were prepared at dierent times following serum stimulation and analysed for E2F stable complex formation using the Ad E2a promoter probe and EMSA. Cells were harvested at 0, 4, 8, 12, 16, 20, 24, 28 and 32 h after growth stimulation (lanes 1 ± 9). Nuclear extract prepared from proliferating SW3T3 cells was analysed in lane 10. The E2F/p130 complex is indicated at the left and the stable E2F/p107 complex is indicated at the right. Lanes 11 ± 16, SW3T3 extracts from growth-arrested cells (t 0 , lanes 11 and 12), 16 h after serum stimulation (lanes 13 and 14), and proliferating cells were analysed for stable E2F complex formation using the E2F single site probe (lanes 11, 13 and 15) or the Ad E2a E2F inverted binding site probe (lanes 12, 14, and 16). Figure  5c ) demonstrated that the stable E2F-4/p107 complex appeared as cells entered S phase of the cell cycle. We conclude that the induction of stable E2F DNA binding by p107 occurs when p107 levels increase during S phase of the cell cycle. (Murthy et al., 1985) . E2a-LS-U and E2a-LS-D did not form the stable E2F/p107 DNA-protein complex, but rather only formed E2F complexes characteristic of E2F single binding sites (Figure 2 , lane 3, and data not shown). Since p107 would be expected to repress transcriptional activation from any promoter to which it is bound, we attempted to detect dierences in the function stable versus unstable E2F complexes by titration of an expression vector for p107. We expected that at low p107 concentrations that a greater level of repression would be observed with inverted E2F binding sites compared to single E2F sites since the formation of stable E2F/p107 complexes would trap repressing complexes at the promoter region. p107 complexes on single E2F sites would bind DNA unstably and thus the promoter may alternatively be activated or repressed depending on p107 occupancy. HepG2 cells were transfected with the three dierent reporter vectors, pCMV-E2F-4 and pCMV-DP-1, and no or increasing amounts of CMVp107. All three reporter vectors were repressed by p107 expression, but to dierent extents ( Figure 6 ). The LS-D and LS-U promoters were repressed 2 and 14% or less, respectively, at the two lower concentrations of p107 expression vector, whereas E2a-WT expression was reduced 36 and 64%. An additive eect of repression of the two individual E2F sites (LS-D+LS-U) would be expected to equal 4 and 27% at the two lower CMV-p107 levels used, whereas the level 
The reporter vectors correspond to E2a-CAT-WT (X ± X), E2a-CAT-LS-U (O ± O), and E2a-CAT-LS-D (& ± &).
The relative CAT expression without exogenouslyexpressed p107 is indicated as 100% for each reporter vector on the y axis. The level of expression of each reporter vector with exogenous p107 coexpression (indicated on the x axis) is given. The data presented represent the mean and standard deviations from the results of quantifying four independent experiments performed in duplicate Figure 7 p130 induces stable E2F binding to inverted E2F binding sites. Nuclear extracts from undierentiated C2C12 cells and cells at day 2 and 4 following the induction of dierentiation were used for EMSA with the Ad E2a E2F inverted site probe. Lanes 1, 4 and 7, standard binding reactions; lanes 2, 5 and 8, binding reactions were incubated for 1 h and then challenged with a 500-fold molar excess of unlabeled E2F site competitor DNA; lanes 3, 6 and 9, binding reactions were challenged with competitor DNA and then an anti-p130 antibody was added to the binding reaction for 20 min prior to EMSA. Free E2F and E2F/p107 complexes found in undierentiated cell extracts are indicated on the left, and the stable E2F/p130 complex is indicated on the right of repression of the wild type E2a promoter was much greater than an additive eect in both cases. At the highest concentration of p107 expression vector, the activities of all three promoters was reduced, but again the wild type promoter was most eectively repressed. p107 repression assays also were performed using an RVS-b-galactosidase expression plasmid as an internal control for transfection eciency. b-gal activity was used to standardize the p107 expression data and the results are in complete agreement with the data shown in Figure 6 (not shown). These results are consistent with the recruitment of stable E2F/p107 complexes to the wild type E2a promoter region to more eectively target promoter repression.
p130 induces stable E2F binding to inverted E2F binding sites
The p130 tumor suppressor is highly related to p107 (Hannon et al., 1993) . Using nuclear extracts from growth-arrested SW3T3 cells, a faint complex was detected that was speci®c to the E2F inverted site probe in comparison to the single site probe ( Figure  5a , lanes 11 and 12), suggestive of the induction of stable E2F binding by p130. To provide a more abundant source of p130 activity, C2C12 myoblasts were induced to dierentiate and nuclear extracts were prepared from dierentiated cells, an abundant source of p130 protein (Shin et al., 1995) . The formation of stable E2F/p130 DNA-protein complexes was assessed by EMSA and competitor challenge (Figure 7) . In undierentiated C2C12 myoblasts, a series of E2F complexes were detected that were not stable to challenge by E2F site competitor DNA (lanes 1 and 2). In dierentiated C2C12 cells, a new complex appeared 2 and 4 days after the induction of dierentiation that was stable to E2F site competitor challenge and that was super-shifted by antibodies against p130 (lanes 5, 6, 8 and 9) . Identical results were obtained using H35 hepatoma cell extracts that express p130 upon growth-arrest, and using p130 expressed with a baculovirus vector and free E2F activity present in HeLa cell S100 cytoplasmic extract (data not shown). We conclude that p130 is capable of inducing stable E2F binding to inverted E2F binding sites.
Discussion
The adenovirus E4-6/7 protein functions to interact directly with E2Fs and mediate the cooperative and stable binding of E2F to a unique pair of inverted E2F binding sites in the Ad E2a promoter (termed E2F induction) (Huang and Hearing, 1989; Marton et al., 1990; Raychaudhuri et al., 1990) . We also described the induction of E2F DNA binding to a similar con®guration of inverted E2F sites in the endogenous cellular E2F-1 promoter (Schaley et al., 2000) . With both promoters, the induction of E2F DNA binding directly correlates with transcriptional activation (Marton et al., 1990; Neill and Nevins, 1991; O'Connor and Hearing, 1991; Obert et al., 1994; Schaley et al., 2000) . The presence of an inverted con®guration of E2F binding sites in a cellular promoter prompted us to test the possibility that the Ad E4-6/7 protein evolved as an analogue to a cellular product with similar binding characteristics. Indeed, we have identi®ed cellular proteins, p107 and p130, that are capable of mediating stable E2F binding to the Ad E2a and cellular E2F-1 promoters. The Ad E4-6/7 protein contains two separate segments that are both required for stable E2F binding in solution (Figure 8 ) (Obert et al., 1994) . A similar result was found with p107 binding to E2F-4 where both the A and B segments of the pocket domain (Figure 8 ) are involved in protein-protein interaction (Zhu et al., 1993a) . In the case of the E4-6/7 protein, these are small segments of around 20 amino acids each. With p107 binding to E2F much larger segments of the protein are required. The Ad E4-6/7 protein provides a dimerization interface to mediate E2F dimerization on inverted E2F binding sites (Figure 8 ) (Obert et al., 1994) . We speculate that p107 may perform a similar function given the slow mobility of the stable E2F/ p107 complex in EMSA in comparison to the mobility of the E4-6/7-induced E2F complex (e.g. Figure 3 ). The requirement for the integrity of both E2F sites in an inverted repeat in order for stable E2F/p107 DNA binding certainly demonstrates that E2Fs are dimerized in the complex. In titration experiments (data not shown) and EMSA assays (e.g. Figure 1 , lanes 2 and 4, Figure 4 , lane 14, Figure 5 , lanes 5 ± 10) two forms of E2F/p107 complexes were evident. The faster migrating complex runs with the mobility of an E2F/p107 complex on a single E2F binding site (Figure 2 , lanes 1 and 2, Figure 4, lanes 13 and 14) . The slower migrating complex represents dimeric E2F and is consistent with the dimerization of p107 as well.
The induction of stable E2F DNA binding by p107 occurred when cells entered S phase in direct correlation to increased levels of p107 protein ( Figure  5) . Thus, the rate limiting step for the formation of a Figure 8 p107 and E4-6/7 domain structure. The p107 coding sequences are shown with the pocket segment, A and B intervals, and spacer region indicated. Shown below are the coding sequences for the Ad E4-6/7 protein with the two segments required for E2F binding in solution indicated as a and b, and the region that mediates E2F dimerization designated as E2F induction p107 regulates E2F DNA binding RJ O'Connor et al stable E2F/p107 DNA bound complex appears to sucient levels of p107, since E2F-4 levels ( Figure 5c ) and DP-1 levels (data not shown) were only modestly increased or were unchanged, respectively, as cells progressed through the cell cycle. The formation of this complex occurs at a time when the transcription of E2F-responsive promoters is decreasing. We hypothesize that the E2F-1 promoter represents one member of a class of E2F-responsive promoters with inverted E2F binding sites. The induction of stable E2F/p107 complexes to such promoters would be expected to recruit HDACs to repress transcription (Adnane et al., 1995; Bremner et al., 1995; Brehm et al., 1998; Ferreira et al., 1998; Luo et al., 1998) ; additionally, stable E2F/107 complexes may repress transcription by physically occluding the binding of other transcription factors to the promoter region. Further, the stable nature of the protein-DNA complex suggests that promoters with such con®gura-tions of binding sites would represent front-line targets of p107 repression. Consistent with this model, the cdc25A promoter contains an inverted con®guration of E2F binding sites (Vigo et al., 1999) and we have found that E2F/p107 complexes bind in a stable manner to this promoter region (data not shown). Like E2F-1, cdc25A is a critical regulator of cell cycle progression (Nilsson and Homann, 2000) and one would anticipate that like E2F-1, precise regulation of cdc25A expression would be essential for appropriate regulation of cell growth. We infer that other promoter regions will be identi®ed with similar characteristics. Although the N-terminal region of Rb has been implicated in Rb protein multimerization (Hensey et al., 1994) , we did not ®nd that Rb induced stable E2F binding to the Ad E2a (Figure 3 ) or cellular E2F-1 promoters (data not shown). In contrast, the p107-related protein, p130, found in growth-arrested and terminally-dierentiated cells, was able to induce stable E2F DNA binding to inverted E2F sites (Figure 7 ). This is not surprising given the close homology that p107 and p130 share (Hannon et al., 1993) . Perhaps Rb did not evolve this function or the experimental conditions that we employed did not reveal such a function.
Finally, we note that not all E2F-4/p107 complexes enter into a stable, dimeric complex on inverted E2F binding sites. For example, E2F-4/ p107 complexes that migrate at the position of those on single E2F binding sites were found using the Ad E2a inverted E2F site probe with HeLa ( Figure 2 , lanes 1 ± 3), SW3T3 ( Figure 5 , lanes 15 and 16) and undierentiated C2C12 cell extracts (Figure 7 , lane 1). These E2F-4/p107 complexes did not bind in a stable manner to DNA as demonstrated using competitor challenge experiments. It may be that monomeric E2F-4/p107 complexes are capable of dimerizing and that the mobility shift assays have trapped intermediates of assembly. Alternatively, the interaction of E2F-4 and/or p107 with additional proteins may preclude dimerization. This could re¯ect another level of regulation of the binding of E2F-4/p107 to DNA.
In conclusion, it appears that adenovirus has transduced cellular mechanisms for protein-protein interactions with E2F and the stabilization of E2F DNA binding. In this manner, the Ad E4-6/7 protein is a cellular analogue to the p107 and p130 tumor suppressor proteins; however E4-6/7 function has been adapted for transcriptional activation instead of repression. This similarity in E2F binding is taken one step further since both E4-6/7 and pocket proteins require common regions of an E2F/DP heterodimer for stable proteinprotein interactions in vivo (i.e. the marked box region of E2F-1 and corresponding region of DP-1) (Helin and Harlow, 1994; O'Connor and Hearing, 1994) . In addition, pocket proteins require additional sequences that overlap the transactivation domain of E2F-1 for stable protein interaction. This interaction would likely mask the sequences that mediate E2F transactivation function. In contrast, the E4-6/7 protein does not require this region for E2F binding and thus leaves the E2F transactivation domain accessible for transcriptional activation of bound promoter regions.
Materials and methods
Extract preparation and gel mobility shift assays
Nuclear and cytoplasmic extracts were prepared according to the method of Dignam and Roeder (Dignam et al., 1983) . The cytoplasmic supernatant obtained after isolation of the nuclei was adjusted to 100 mM KCl, spun at 100 0006g for 1 h, and saved as the cytoplasmic fraction. Cytoplasmic and nuclear fractions were dialysed against DB (20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH 7.5, 100 mM KCl, 10% glycerol, 5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF) and the dialysate was cleared by centrifugation at 25 0006g. In vitro DNA binding assays were performed as described previously . Brie¯y, binding reaction mixtures (20 ml) contained 5 ± 10 mg of nuclear or cytoplasmic extract, 2 mg of sonicated salmon sperm DNA, and 20 000 c.p.m. (double-site probe) or 40 000 c.p.m. (single-site probe) of 32 P-labeled E2F recognition sites (1 ± 2 fmol of DNA) in DB supplemented with Nonidet P-40 (®nal concentration, 0.1%). Binding reactions were incubated for 1 ± 2 h at room temperature, followed by electrophoresis on a 4% 30 : 1 polyacrylamide gel run in 0.56TBE at 48C. The Ad5 E2a E2F double-site probe contains nucleotides 730 to 773 from the Ad5 E2a promoter plus additional vector sequences; the sequence of one strand is 5'-AATTCGTAGTTTTCGCGCTTAAATTT-GAGAAAGGGCGCGAAACTAGTCCCGG-3'. The E2F sites are underlined and vector sequences are shown in italics. The E2F single-site probe contains Ad nucleotides 270 ± 293 from the E1A enhancer and¯anking vector sequences; the sequence of one strand is: 5'-AATTCCCC-CATTTTCGCGGGAAAACTGAATCCTCGA-3'. The cellular E2F-1 promoter probe corresponds to nucleotides 744 to 712 (Hsiao et al., 1994; Johnson et al., 1994) ; the sequence of one strand is: 5'-AATTCCGGGCTCTTTC-GCGGCAAAAAGGATTTGGCGCGTAAAAGG-3'. Probe fragments were labeled with a 32 P-dATP and Klenow DNA polymerase; speci®c activities were 5000 ± 10 000 c.p.m./fmol.
For bacterial expression of E4-6/7, p107 and Rb, a 50 ml overnight culture of E. coli (DH5) transformed with pGEX-E4-6/7 (O'Connor and Hearing, 1994), pGST-107 (Ewen et al., 1992) or pGST-Rb (Kaelin et al., 1992) was grown overnight to saturation. A 500 ml culture was then inoculated and allowed to grow for 1 h. IPTG was added to 0.1 mM and incubation was continued for 4 h at 378C for pGEX-E4-6/7 and for 5 h at 308C for pGEX-107 and pGEX-Rb. Bacteria were harvested, washed with PBS+1 mM PMSF, and resuspended in 25 ml TNE (10 mM TRIS, pH 7.5, 100 mM NaCl, 1 mM EDTA) containing 10 mM dithiothreitol, 1 mM PMSF and 1% Triton X-100. Aliquots were sonicated and soluble material recovered following centrifugation at 25 0006g for 20 min. The soluble pool was loaded on a column of glutathione-agarose (Sigma), the bound material washed with DB-100, and GST-ORF7 protein was eluted in DB-100+20 mM reduced glutathione. pGST-107 was provided by M Ewen and pGST-Rb was provided by W Kaelin.
Bacterial expression of human DP-1 and human E2F-4 was conducted as previously described for E2F-1 (O' Connor and Hearing, 1994) . Ten ml cultures of BL21(DE3) lysogen (Studier et al., 1990) transformed with pET-3a-hDP-1 or pET-3c-hE2F-4 were grown overnight to saturation. The 10 ml cultures were used to inoculate 100 ml cultures and allowed to grow for 1 h at 378C. IPTG was then added to a ®nal concentration of 0.1 mM and incubation was continued for 4 h at 378C. Bacterial pellets were collected by centrifugation, washed once in PBS+1 mM PMSF, and resuspended in 2 ml of TNE (50 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA)+1 mM PMSF. Bacteria were lysed by incubation with lysozyme+0.1% deoxycholic acid and subsequent digestion with DNase I. Inclusion bodies containing the overexpressed E2F-4 and DP-1 proteins were isolated by centrifugation, washed three times with TNE+PMSF. Bacterially-expressed DP-1 and E2F-4 were solubilized in DB-100 containing 8 M urea+100 mg/ml BSA. DP-1 and E2F-4 were mixed at appropriate dilutions and diluted into DB-100 to allow protein renaturation by incubation at room temperature for 10 min. Renatured E2F-4/DP-1 heterodimers were then added to in vitro DNA binding reactions.
Cells, Western blot analysis and transfection assays
SW3T3 and 293T cells were maintained in Dulbecco's modi®ed minimal essential medium (DMEM) containing 10% calf serum. HepG2 cells were maintained in minimal essential medium (MEM) containing 10% fetal bovine serum. C2C12 cells were maintained in DMEM containing 20% fetal bovine serum. For cell cycle analyses, SW3T3 cells were split 1 : 10 and the cells in monolayer cultures were allowed to reach con¯uence. The cells were washed and incubated in DMEM containing 0.25% calf serum for 24 h. The cells were then scraped from the plates and replated at a 1 : 3 dilution in DMEM containing 10% fetal bovine serum. Nuclear extracts were prepared as described above. Cells were evaluated bȳ uorescent activated cell sorting following propidium iodide staining as described (Buchkovich et al., 1989) . Proteins in SW3T3 nuclear extracts were resolved by SDS ± PAGE and analysed by Western blot, as described, using antibodies from Santa Cruz Biotechnology: anti-E2F-4 (SC-866), anti-p107 (SC-318), anti-cyclin A (SC-751) and anti-cyclin D1 (SC-718). Proteins were visualized by enhanced chemiluminescence (Amersham). C2C12 cells were induced to dierentiate by maintaining the cells in DMEM containing 2% horse serum and 12 mg/ml bovine insulin (Sigma) followed by incubation for 2 or 4 days. C2C12 cells were provided by J Wells and S Strickland.
Plasmid DNA transfections were performed by the calcium phosphate precipitation procedure (Wigler et al., 1977) . HepG2 cells were split and plated the day before transfection. The following day, the cells were transfected with 2 mg of the dierent E2a-CAT reporter plasmid DNAs (E2a-WT, E2a-LS-63/-73 termed LS-U, and E2a-LS-35/-46 termed LS-D; Murthy et al., 1985) , 200 ng pCMV-E2F-4, 200 ng pCMV-DP-1, 18 mg of salmon sperm DNA, and varying amounts of CMV-p107 eector plasmid per 100 mm dish, as indicated in the ®gure. The total amount of CMV expression vector in each transfection was held constant (5 mg) by the addition of empty CMV vector DNA. The cells were incubated for 4 h with the calcium phosphate precipitate, the medium was removed and Tris-buer saline solution (TS) containing 20% glycerol was added for 1 min. The cells were then washed three times with TS, and fresh medium containing 10% serum was added. Total cell extracts were prepared 24 h later, and chloramphenicol acetyltransferase (CAT) enzymatic activity in cellular extracts was assayed using a¯uorescent chloramphenicol substrate (FAST-CAT, Molecular Probes, Eugene, OR, USA). CAT activity was quanti®ed using a phosphoimager. The results presented represent the average of four experiments performed in duplicate. For p107/E2F-4 protein expression studies, 293T cells were transfected with 5 mg CMV-hE2F-4, 2.5 mg CMV-hDP-1, and 5 mg CMVp107 per 100 mm dish. Twenty-four hours after transfection, total cell extracts were prepared as described (Helin et al., 1993) .
